SCHEMBL4859908

SCHEMBL4859908

CCOC(=O)c1oc2ncccc2c1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.46
AHR P35869 1/20 0.45
PLK1 P53350 1/20 0.43
HPGD P15428 5/20 0.43
HSD17B10 Q99714 4/20 0.43
ALDH1A1 P00352 3/20 0.43
LMNA P02545 2/20 0.43
HTT P42858 1/20 0.43
BRD4 O60885 1/20 0.41
TSHR P16473 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GABRP O00591 1/20 0.41
GABRD O14764 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRB1 P18505 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
GABRA2 P47869 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL845028 0.84 KDM4E (0.47) KDM4EAHRPLK1HPGDALDH1A1
SCHEMBL29730728 0.83 KDM4E (0.63) KDM4EAHRPLK1HPGDHSD17B10
SCHEMBL259266 0.83 KDM4E (0.63) KDM4EAHRPLK1HPGDHSD17B10
SCHEMBL4851465 0.82 KDM4E (0.40) KDM4EHPGDHSD17B10ALDH1A1HTT
SCHEMBL842839 0.81 KDM4E (0.39) KDM4EAHRPLK1HPGDALDH1A1
SCHEMBL4854522 0.79 KDM4E (0.48) KDM4EAHRPLK1HPGDHSD17B10
SCHEMBL13102749 0.79 LMNA (0.51) KDM4EHPGDHSD17B10ALDH1A1LMNA
SCHEMBL8482263 0.78 KDM4E (0.68) KDM4EAHRPLK1HPGDHSD17B10
SCHEMBL31475455 0.78 KDM4E (0.68) KDM4EAHRPLK1HPGDHSD17B10
SCHEMBL259251 0.77 KDM4E (0.58) KDM4EHPGDHSD17B10ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456192-B2 3β-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof PIERRE FABRE MEDICAMENT (FR) 2008-11-25 US disclosed
EP-1440075-B1 NOVEL 3BETA-AMINO AZABICYCLOOCTANE HETEROAROMATIC AMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USES THEREOF PF MEDICAMENT (FR) 2005-06-08 EP disclosed
US-20050080085-A1 Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof PIERRE FABRE MEDICAMENT (FR) 2005-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080085-A1 Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof AOC3, MAOB, AOC1 KDM4E 2970/4885AHR 1109/4885PLK1 4013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.